Marco Agostini

25PUBLICATIONS
90CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 13, 2026
Protein Glycosylation and Its Role in Current Immunotherapeutic Strategies.

|Jun 26, 2026
Ill Fate of Rectal Mucinous Adenocarcinoma: A Defect in Immunosurveillance or a Mucin Coating Effect?-The IMMUNOREACT 20 Study.

|Jun 25, 2026
Immune Cell Therapy Promises More Effective Cure for Medulloblastoma.

|Feb 27, 2026
IMMUNOREACT 4: Peritumoral Microenvironment Associated with Anastomotic Leaks After Surgery for Rectal Cancer.

Ottavia De Simoni, Melania Scarpa, Francesco Cavallin

|Feb 12, 2026
Does the B7-H3 Immune Checkpoint Have High Potential as a Therapeutic Target?

Marco Agostini, Pietro Traldi, Mahmoud Hamdan

|Dec 24, 2025
The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events.

Marco Agostini, Pietro Traldi, Mahmoud Hamdan

Pageof 5

Frequent Collaborators

7 joint publications

Pietro Traldi

5 joint publications

Edoardo D'Angelo

4 joint publications

Sara Crotti

4 joint publications

Salvatore Pucciarelli